Key in Medical Technology

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Radius Health ("Radius") today announced topline Phase 2 data demonstrating that in women with osteoporosis, BA058 -- the company's novel PTHrP (parathyroid hormone-related protein) analog -- significantly increased bone mineral density (BM...

VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE

BEDFORD, Mass., July 30 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that scientists reporting in the July 31 issue of SCIENCE have discovered a key disease-related biologic pathway using an integrated and ...

New Review on PROSTVAC(TM) Published by Key Investigators From NCI

KVISTGAARD, Denmark, July 1 /PRNewswire-FirstCall/ -- A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information on PROSTVAC(TM). This is the most comprehensive and updated Review on PROSTVAC(TM) so...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

RICHMOND, Calif., June 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that a key research milestone has been achieved in its Research and License Agreement with Genentech, Inc., a wholly-owned member of the Roche Group, for the generation of cell lines wit...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

Pivotal Trial Expected to Initiate in 2010 for Blinatumomab NEW YORK, April 24 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today held an R&am...

New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management

TRILIPIX has now been studied in combination with the most commonly used doses of rosuvastatin calcium (5 mg, 10 mg, 20 mg) in patients with mixed dyslipidemia ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Data from a new study showed that Abbott 's TRILIPIX(R) (fenofibric acid) delayed-...

Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments

- Positive results for first Albuferon(R) Phase 3 trial announced in December 2008; data from second trial expected March 2009 - - Phase 3 trials of darapladib for cardiovascular disease and Syncria(R) for type 2 diabetes initiated by GlaxoSmithKline (GSK) - - $106 million of conv...

Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells

Proves significance of AHCC for maintaining a healthy immune system PURCHASE, N.Y., Jan. 6 /PRNewswire/ -- A recently published study in Nutrition and Cancer (60(5), 643-651) by researchers at Kansai Medical University in Osaka, Japan has shown that AHCC (Active Hexose Correlated Compound) ...

Micromet Key Events for 2009

BETHESDA, Md., Jan. 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, provides an outlook on key events anticipated for the year 2009. Mic...

Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds

- Not Intended for Journalists in the UK or Ireland - New Findings From ARTEMIS and TITAN Studies Demonstrate Growth of the Tibotec Virology Franchise GLASGOW, Scotland, Nov. 12 /PRNewswire/ -- New data on PREZISTA(R) (darunavir), a protease inhibitor from Tib...

Aiming at Multiple Alzheimer's Proteins May be Key to Success

CLARKSBURG, Md., Oct. 21 /PRNewswire/ -- An independent team of scientists is leading Alzheimer's disease research in a new, promising direction. Through a $1 million grant they received last year from Alzheimer's Disease Research, a program of the American Health Assistance Foundation (AHAF),...

Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years

New Analysis of SPIRIT II and SPIRIT III Data Confirms Patients Treated with XIENCE V Are at Lower Risk of Experiencing Death, a Heart Attack or a Repeat Procedure Compared to TAXUS(R) at Two Years WASHINGTON, Oct. 13 /PRNewswire-FirstCall/ -- Data from an independent meta-analysis ...

Protein Shown to Play a Key Role in Normal Development of Nervous System

- Findings May Someday Inform Treatments for Spinal Cord, Other Nerve Injuries - PHILADELPHIA, Oct. 8 /PRNewswire-USNewswire/ -- A protein that enables nerve cells to communicate with each other plays a key role in controlling the developing nervous system. Research into how that protein hel...

Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch

Company to Discuss Phase 3 Plans with FDA PRINCETON, N.J., Sept. 3 /PRNewswire/ -- Agile Therapeutics, Inc., announced today that it successfully completed two key clinical trials in the development of the company's new, innovative low-dose, once-weekly, contraceptive patch, whi...

Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent

SAN DIEGO, Aug. 12 /PRNewswire/ -- Novalar Pharmaceuticals, Inc., a dental specialty pharmaceutical company, announced the publication of three clinical trials on the use of OraVerse (phentolamine mesylate) injection as a local dental anesthetic reversal agent in the August 2008 issue of the J...

Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling

Intercept Pharmaceuticals is Advancing Bile Acid-Derived Small Molecules with Potential Applications in Treating Metabolic Diseases NEW YORK, Aug. 7 /PRNewswire/ -- Historically, bile acids have been recognized primarily as natural detergents that regulate the absorption of dietary lipid...

Protein Key to Control Growth of Blood Cells

--Findings May Aid in Bone Marrow Transplants, Blood Diseases-- PHILADELPHIA, Aug. 5 /PRNewswire-USNewswire/ -- New research sheds light on the biological events by which stem cells in the bone marrow develop into the broad variety of cells that circulate in the blood. The findings may hel...

InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

SAN FRANCISCO, July 23 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging biopharmaceutical company, today announced preclinical test results demonstrating the utility of their lead drug candidate rC3-1 for the treatment of the rare chronic blood disorder paroxysmal nocturnal hemoglobi...

International Team Locates Key Player in Muscle Regeneration

PHILADELPHIA, June 27 /PRNewswire-USNewswire/ -- A new understanding of the role played by the protein cdk9-55 in muscle regeneration and differentiation may lead to novel therapies to rebuild muscle tissue damaged by disease, injury and aging, according to researchers at the Sbarro Institute ...

Stroke Study Reveals a Key Target For Improving Treatment

Research in mice shows why tPA carries risks as well as benefits, and suggests that Gleevec or other drugs could prevent problems ANN ARBOR, Mich., June 22 /PRNewswire-USNewswire/ -- For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the...

Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair

Study Showing Results of Tengion Neo-Bladder Augment(TM) to be Featured in July Issue of the Journal of Urology EAST NORRITON, Pa., June 12 /PRNewswire/ -- Tengion, Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-tissues, announced ...

New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder

First Extensive Report of Bile Acid Aberration in Type 2 Diabetes Patients Warrants Further Study EMERYVILLE, Calif. and PARSIPPANY, N.J., June 9 /PRNewswire-FirstCall/ -- KineMed, Inc., and Daiichi Sankyo, Inc., announced that researchers have discovered a key differenc...

Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes

TriLipix in Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects in Patients with Diabetes and Overall Study Population SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- New data from a sub-group analysis of patients with mixed dyslip...

DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes

Additional Studies Indicate GlycoMark May Be a More Effective Monitor Than Hemoglobin A1C of Exenatide, Sitagliptin, Pramlintide and Prandial Insulin Therapies in Certain Diabetic Populations SAN FRANCISCO, June 7 /PRNewswire/ -- GlycoMark, Inc. announced today results from the o...

Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids

Data Show TriLipix (ABT-335) in Combination with CRESTOR (rosuvastatin calcium) Improved LDL, HDL and Triglycerides and Had Reported Safety Consistent with Monotherapies SEATTLE, May 31 /PRNewswire-FirstCall/ -- New Phase III data showed that in patients with multiple lip...

Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day

MONTVALE, N.J., May 16 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demo...

CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence

BOSTON, May 15 /PRNewswire/ -- CenterWatch, a publishing and information services company focused on market research about clinical trials, finds that investigative sites are required to learn multiple EDC (electronic data capture) systems. More than 75% of respondents to a recent CenterWatch ...

St. Jude Finds 'Dancing' Hair Cells Are Key to Humans' Acute Hearing

A new study shows how sounds are amplified in the inner ear, a finding that could explain how hearing loss can result from genetic mutation or overdose of drugs MEMPHIS, Tenn., May 7 /PRNewswire-USNewswire/ -- St. Jude Children's Research Hospital investigators have found that an electrica...

California Stem Cell Agency Exaggerated Its Role in Funding Key Research

Agency Claimed State Funding Led to Important Clinical Trials SANTA MONICA, Calif., April 16 /PRNewswire-USNewswire/ -- California's stem cell agency overstated and hyped the importance of its funding in enabling clinical trials for a drug to treat a severe blood disorder, Consumer Watchdo...

Genta Receives Key Patent Related to Oral Gallium Compound G4544

Company to Seek Buyer for Marketed Parenteral Product Ganite(R) BERKELEY HEIGHTS, N.J., April 14 /PRNewswire/ -- Genta Incorporated (Nasdaq: GNTA ) today announced that the Company has received notice that its patent application covering novel pharmaceutical gallium compositions and compl...

EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program

Selective Kinase Inhibitor Phase 1 Trial in Advanced Cancer Patients ROCKVILLE, Md., April 9, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced...

Velos to Develop Key System Interface for Clinical Research

- Will facilitate tight integration between sponsors and investigators - FREMONT, Calif., March 26 /PRNewswire/ -- Velos, Inc., a recognized leader and trusted resource for clinical trial management information systems and member of the Oracle PartnerNetwork, will work to develop a key interfa...

NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones

ANN ARBOR, Mich., March 6 /PRNewswire/ -- NanoBio(R) Corporation has received its third $10 million tranche of equity funding from Perseus LLC, after having successfully met three critical development milestones: validating the efficacy and safety of its two topical treatments for skin infecti...

Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)

FREDERICK, Md., Feb. 11 /PRNewswire/ -- Cancer research pioneer Michael G. Hanna Jr. Ph.D., also Vaccinogen, Inc.'s Founder, Chairman and CEO has acquired the rights to OncoVAX(R), a vaccine with the potential to prevent colon cancer from recurring in many patients. "This agreement represent...

Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease

BOSTON, Feb. 5 /PRNewswire-USNewswire/ -- A new study led by researchers at Joslin Diabetes Center has identified insulin resistance in the liver as a key factor in the cause of metabolic syndrome and its associated atherosclerosis, disorders that put tens of millions of Americans at high risk...

Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes

New Patient Data Posted Online Shows Improvements Across Care Center Network BETHESDA, Md., Jan. 28 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation reported today that key indicators of health for people with cystic fibrosis -- including lung function and nutritional status -- ar...

U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences' Claims

NEW YORK, Jan. 23 /PRNewswire-USNewswire/ -- The Public Patent Foundation ("PUBPAT") announced today that the U.S. Patent & Trademark Office has rejected four key HIV/AIDS drug patents held by Gilead Sciences that relate to the drug known generically as tenofovir disoproxil fumarate (TDF), a k...

Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem

SWEDESBORO, N.J., Dec. 3 /PRNewswire/ -- Wedgewood Pharmacy has introduced the Refresh(TM) exchange-program, which lets veterinarians return expired custom-compounded medications for exchange, at no cost. The program is a compounding-pharmacy profession first. Through the program, the company ...

NxStage(R) to Recognize Several Key Milestones at American Society of Nephrology's Renal Week 2007

Number of active users of NxStage Home Hemodialysis System exceeds 2007 patients in 2007, having increased 290 percent in past 18 months Seven of the Top Ten Hospitals for Kidney Disease are now NxStage Partners NxStage closes acquisition of Medisystems and announces launch of inno...

First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs

HWI Scientist Dr. Dan Gewirth's Groundbreaking Research Makes Cover of Molecular Cell BUFFALO, N.Y., Oct. 19 /PRNewswire/ -- Dr. Dan Gewirth, Hauptman-Woodward senior research scientist, has just solved the structure of the first mammalian GRP94 protein implicated ...